13036_2019_189_MOESM1_ESM.doc (1.9 MB)

Additional file 1: of Intestinal probiotics E. coli Nissle 1917 as a targeted vehicle for delivery of p53 and Tum-5 to solid tumors for cancer therapy

Download (1.9 MB)
journal contribution
posted on 28.06.2019, 05:00 by Lian He, Huijun Yang, Jianli Tang, Zhudong Liu, Yiyan Chen, Binghua Lu, Haocheng He, Sijia Tang, Yunjun Sun, Fei Liu, Xuezhi Ding, Youming Zhang, Shengbiao Hu, Liqiu Xia
Table S1. Primers used in PCR amplification. Figure S1. Agarose gel electrophoresis of human p53 gene amplification products. Figure S2. Construction and identification of recombinant plasmid pET28a-p18. Figure S3. Construction and identification of plasmid pET28a-p18-p53. Figure S4. Purification and identification of recombinant p53 protein. Figure S5. Inhibitory effect of recombinant p53 protein on different tumor cells. Figure S6. The construction program of hypoxia expression vector pET28a-Pvhb-pelB-p18-p53. Figure S7. Construction of p53 hypoxia expression vector pET28a-Pvhb-pelB-p18-p53. Figure S8. Construction of p53 and Tum-5 fusion expression vector. Figure S9. Construction of Tum-5 and p53 fusion expression vector. Figure S10. Morphological changes of different tumor cells after recombinant Tum 5-p53 treated (100×). Figure S11. The construction process diagram of hypoxia expression vector pET28a-Pvhb-pelB-SUMO-Tum 5-MMP-p53. Figure S12. Construction of recombinant plasmid pET28a-Pvhb-pelB-SUMO-Tum 5-MMP-p53 (DOC 1943 kb)

Funding

the National Basic Research Program (973) of China

History

Exports